BioCryst Pharmaceuticals
BCRX
191 hedge funds and large institutions have $1.06B invested in BioCryst Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 57 increasing their positions, 71 reducing their positions, and 31 closing their positions.
60% more call options, than puts
Call options by funds: $37.2M | Put options by funds: $23.2M
48% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 31
18% more capital invested
Capital invested by funds: $898M → $1.06B (+$165M)
8% more funds holding
Funds holding: 177 → 191 (+14)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9.22% less ownership
Funds ownership: 68.29% → 59.07% (-9.2%)
20% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$50.4M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$31.2M |
| 3 |
Goldman Sachs
New York
|
+$19.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$14.4M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$58.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$38.6M |
| 3 |
DM
Deerfield Management
New York
|
-$33.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.1M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$19.9M |
BCRX Hedge Fund Activity: Q1 2021 in Review
191 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2021, worth a combined $1.06B — up 18% from $898M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new BCRX positions and 31 closed out — a net gain of 15 holders — while 57 added to existing stakes and 71 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $50.4M. The largest seller was Citadel Advisors, cutting an estimated $58.7M.
- 191 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2021, up from 177 in Q4 2020.
- Funds reported $1.06B of BioCryst Pharmaceuticals stock for Q1 2021, up 18% quarter-over-quarter.
- 46 funds opened new BioCryst Pharmaceuticals positions in Q1 2021 and 31 closed out, a net change of +15 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2021 was HealthCor Management, an estimated $50.4M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2021 was Citadel Advisors, an estimated $58.7M sold.
Based on aggregated 13F filings for Q1 2021.